4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 91 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,750,758 | -5.5% | 137,530 | +34.2% | 0.00% | – |
| Q2 2023 | $1,852,320 | -44.1% | 102,508 | -46.9% | 0.00% | – |
| Q1 2023 | $3,315,660 | +92.8% | 192,883 | +149.2% | 0.00% | – |
| Q4 2022 | $1,719,320 | +974.6% | 77,412 | +288.9% | 0.00% | – |
| Q3 2022 | $160,000 | +4.6% | 19,903 | -9.3% | 0.00% | – |
| Q2 2022 | $153,000 | -90.6% | 21,947 | -79.7% | 0.00% | – |
| Q1 2022 | $1,633,000 | -14.9% | 107,980 | +23.5% | 0.00% | – |
| Q4 2021 | $1,918,000 | +462.5% | 87,447 | +592.8% | 0.00% | – |
| Q3 2021 | $341,000 | +28.7% | 12,623 | +14.6% | 0.00% | – |
| Q2 2021 | $265,000 | -10.8% | 11,015 | +60.2% | 0.00% | – |
| Q1 2021 | $297,000 | +14750.0% | 6,877 | +17092.5% | 0.00% | – |
| Q4 2020 | $2,000 | – | 40 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,007,413 | $68,887,429 | 2.52% |
| Opaleye Management Inc. | 314,000 | $5,397,660 | 1.62% |
| Deep Track Capital, LP | 2,278,107 | $39,160,659 | 1.61% |
| Casdin Capital, LLC | 1,070,000 | $18,393,300 | 1.52% |
| Eagle Health Investments LP | 437,911 | $7,527,690 | 1.46% |
| ACUTA CAPITAL PARTNERS, LLC | 104,753 | $1,800,704 | 1.33% |
| Octagon Capital Advisors LP | 499,996 | $8,594,931 | 1.24% |
| Soleus Capital Management, L.P. | 469,400 | $8,068,986 | 0.84% |
| Novo Holdings A/S | 700,000 | $12,033,000 | 0.79% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $67,692,742 | 0.32% |